Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category.

Bedossa P, Burt AD, Brunt EM, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2014 Mar;45(3):658-60. doi: 10.1016/j.humpath.2013.09.020. Epub 2013 Nov 21. No abstract available.

PMID:
24529331
2.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category--reply.

Kakar S, Evason KJ, Ferrell LD.

Hum Pathol. 2014 Mar;45(3):660-1. doi: 10.1016/j.humpath.2013.09.019. Epub 2013 Nov 21. No abstract available.

PMID:
24529332
3.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential.

Balabaud C, Bioulac-Sage P, Ferrell L, Kakar S, Paradis V, Quaglia A, Sempoux C, Thung S, Zucman-Rossi J.

Hum Pathol. 2015 Apr;46(4):634-5. doi: 10.1016/j.humpath.2014.10.029. Epub 2014 Dec 31. No abstract available.

PMID:
25661243
4.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.

Bedossa P, Burt AD, Brunt E, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2015 Apr;46(4):635-6. doi: 10.1016/j.humpath.2014.10.030. Epub 2014 Dec 31. No abstract available.

PMID:
25732109
5.

Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas.

Evason KJ, Grenert JP, Ferrell LD, Kakar S.

Hum Pathol. 2013 May;44(5):750-8. doi: 10.1016/j.humpath.2012.07.019. Epub 2012 Oct 16.

PMID:
23084586
6.

TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.

Pinyol R, Tovar V, Llovet JM.

J Hepatol. 2014 Sep;61(3):685-7. doi: 10.1016/j.jhep.2014.05.028. Epub 2014 May 22. No abstract available.

7.

Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.

Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P.

Hepatology. 2006 Mar;43(3):515-24.

PMID:
16496320
8.

Malignant transformation of hepatic adenomas.

Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M.

Mod Pathol. 2008 Apr;21(4):491-7. doi: 10.1038/modpathol.2008.8. Epub 2008 Feb 1.

9.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J.

Nat Commun. 2013;4:2218. doi: 10.1038/ncomms3218. Erratum in: Nat Commun. 2013;4:2577. Zucman Rossi, Jessica [corrected to Zucman-Rossi, Jessica].

10.

Comparison of the DNA content in liver cell adenoma, hepatocellular carcinoma and regenerative nodules.

Ruschenburg I, Hofmann M, Diab E, Droese M.

Anticancer Res. 2000 May-Jun;20(3A):1861-4.

PMID:
10928119
11.

Hepatic adenomas: presumed innocent until proven to be beta-catenin mutated.

Monga SP.

Hepatology. 2006 Mar;43(3):401-4. No abstract available.

PMID:
16496344
12.
13.

Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care.

Marquardt JU, Thorgeirsson SS.

Cancer Cell. 2014 Apr 14;25(4):409-11. doi: 10.1016/j.ccr.2014.03.032.

14.

Genetic mutation in hepatic adenoma: seeing is believing.

Chen PJ.

J Hepatol. 2006 Dec;45(6):767-9. Epub 2006 Sep 25. No abstract available.

PMID:
17034896
15.

Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis.

Devereux TR, Anna CH, Foley JF, White CM, Sills RC, Barrett JC.

Oncogene. 1999 Aug 19;18(33):4726-33.

16.

Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling.

Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H, Flemming P.

Clin Cancer Res. 2005 May 15;11(10):3654-60.

17.

[Highly differentiated liver tumors: recent developments and their diagnostic application].

Schirmacher P, Longerich T.

Pathologe. 2009 Dec;30 Suppl 2:200-6. doi: 10.1007/s00292-009-1214-4. German.

PMID:
19908045
18.

Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.

Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G, Mallet M, Taouji S, Balabaud C, Terris B, Canal F, Paradis V, Scoazec JY, de Muret A, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-Rossi J.

Cancer Cell. 2014 Apr 14;25(4):428-41. doi: 10.1016/j.ccr.2014.03.005.

19.

Genetics and imaging of hepatocellular adenomas: 2011 update.

Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR.

Radiographics. 2011 Oct;31(6):1529-43. doi: 10.1148/rg.316115527. Review.

PMID:
21997980
20.

Subtype classification of hepatocellular adenoma.

Bioulac-Sage P, Balabaud C, Zucman-Rossi J.

Dig Surg. 2010;27(1):39-45. doi: 10.1159/000268406. Epub 2010 Apr 1.

PMID:
20357450
Items per page

Supplemental Content

Write to the Help Desk